THE CATIONIC PEPTIDES OF NATURE
No therapeutically useful new classes of antibiotics have been identified in the past quarter of a century This has become of major consequence in the face of the increase in the incidence of significant antibiotic resistance in the past decade. Indeed, strains of several important pathogens have been identified for which very few, or even no, possibilities for antibiotic therapy exist. Although several broad-spectrum improved variants of existing antibiotic classes have been produced (e.g. new fluoroquinolones, imipenem), it seems that bacteria can relatively easily become resistant to these by modulation of known resistance mechanisms. For this reason there is great interest in identifying novel antibiotic classes with potential in human therapeutics.
Human beings and other species are continually exposed to numerous bacteria. Even in the absence of an immune response, they rarely become infected because of the potency of their so-called non-specific defenses. Thus, it is worth looking to these defenses as a potential source of new antimicrobial strategies. In the past decade it has become apparent that many organisms use cationic peptides as a major non-specific defense against infections (Table 1) . Indeed, more than 140 cationic peptides are known, having been identified in nearly every species of life [l] . In plants (e.g. thionins) and insects (e.g. cecropins and insect defensins), cationic peptides provide the predominant mechanism of defense against bacteria and fungi. In insects, such peptides are inducible by mechanisms that closely resemble immune response regulation [2] . Among aniphibians, cationic peptides (eg. magainins) constitute the major protection for the skins of frogs and toads, which almost never become infected, despite their exposure to enormous numbers of potential pathogens. In higher animals, including humans, cationic peptides (e.g. defensins) are the major protein species (-8-15% of total proteins) in neutrophils, which are the most important cells in the non-specific defense of the body against invasive pathogens. In addition, other cationic peptides are found in high concentrations at niucosal surfaces; for example, lingual antimicrobial peptide, tracheal antimicrobial peptide and cecropin P1 are considered by some to contribute significantly to mucosal immunity [3] . Cationic peptides are also produced by bacteria, fungi and crustaceans. Thus they can truly be described ubiquitous. This brief review presents an overview of the cationic peptides. For more details, the reader is referred to our more extensive review [l] .
THE NATURE OF CATIONIC PEPTIDES
Cationic peptides are perhaps the finest example of convergent evolution, in which diverse molecules have evolved towards a coninion function: the ability to kill infectious microbes. However, it is clear that the differences between the peptides with this common function are as profound as the similarities. All cationic peptides consist of sequences of between 12 and about 40 amino acids. These sequences usually contain two to six positively charged amino acids (lysine or arginine) and rarely more than one negatively charged amino acid. Another similarity is that such molecules can fold in three dimensions, under the appropriate conditions, which usually involve incorporation in a membrane, to present a hydrophobic face and a hydrophilic face (Figure 1 ), the latter of which contains the charged amino acids. Within this coninion structure, however, many variations exist. For example, the uncharged amino acids are usually restricted to a subset o f amino acids, but the identity of the specific amino acids from this subset varies substantially from species to species. In addition, unusual amino acids (e.g. laiithionine) are often found i n bacterial cationic peptides (e.g. nisin), and modified C-and N-terminal amino acids are also quite common. More importantly, the secondary and tertiary structures of the peptides can vary, including P-structured peptides with strands stabilized by disulfide bridges [4,5], a-helices [6, 7] and more extended structures (Hancock and Falla, unpublished). T h e four general classes of cationic peptides recognized in the literature are P-structured peptides, a-helical peptides, loop structures created by a cysteine disulfide bridge and peptides with a predominance of a single aniino acid (Trp, Pro or His).
ANTIMICROBIAL ACTIVITIES
T h e spectrum of antimicrobial activity of cationic peptides varies, to include broad-spectrum antibacterial activity, selectivity for either Gram-negative or G r a npositive bacteria, and antifungal action 111. It must be stated that the above MICs are increased in the presence of high concentrations of divalent cations. Although this may reflect, in part, competition for bacterial surface binding sites, our recent experiments indicate that there may be a more trivial explanation for this phenomenon, and we are currently attempting to define this more fully. In addition to direct antimicrobial activity, cationic peptides have two other usefd activities against bacteria. First, they can act as 'enhancers' of conventional antibiotics by showing synergy in vitro with such antibiotics. The cationic peptide polyniyxin B nonapeptide has been well characterized with respect to this property [lo] . Also, clear synergy has been demonstrated between the peptide niagainin and cefpirome in a mouse infection model, even though the magainin was ineffective by itself [ll] . Second, unlike some conventional antibiotics which release endotoxin from bacteria and contribute to the development of endotoxemia, cationic peptides actually bind endotoxin and prevent it from inducing tumor necrosis factor, and they substantially reduce endotoxic shock in galactosamine-sensitized mice [9] .
OTHER ACTIVITIES OF CATIONIC PEPTIDES
Numerous other activities have been demonstrated for individual cationic peptides. These include activity against pathogenic protozoa 112,131 and enveloped viruses [14] , anticancer activity [15] , antiprotease activity [16] , a role in insect development [17] , and an ability to promote re-epithelialization of damaged tissues.
PRODUCTION
Despite the relatively high levels of cationic peptides within specific tissues, it is impractical to use such natural sources for high-level production. More commonly protein chemical methods are used for synthesis. However, even using the most refined new methods of peptide synthesis (solution-phase chemistry), it is quite expensive to produce peptides by this route, and this may limit potential clinical usage. An interesting possibility is provided by recombinant DNA technology, in which the peptides are produced as parts of fusion proteins encoded by plasmids. This method [lS] can be used to produce virtually any cationic peptide sequence in quite high yields (approximately 2% of bacterial cell biomass) using the classical methodology of bacterial fermentation. We believe that this method will yield peptides in large enough amounts, and inexpensively enough, to make clinical use practicable.
MODE OF ACTION
The actual mechanism of bacterial killing by cationic peptides involves the formation of channels in the cytoplasmic membranes of the target bacteria 111. Model membrane studies have suggested that such channels are of two types, multistate channels, in which different numbers of peptides participate in forming individual channels (more subunits = bigger channels), and channels of defined size, which presumably involve some energetically favored number of subunits in a fixed arrangement [ 19,201. For example, two niolecular models for channel formation by cecropin have been proposed by Durell et a1 [20] . These contain the arrangement of six dimers in star and circular conformations, producing channel sizes consistent with two experimental conductance increments observed by Christensen et a1 [21] . Bacterial cells are then killed because of the leakage of ions and essential chemicals from the cell. Some features of channel formation suggest the basis for peptide selectivity, in that channel formation requires a high transnieinbrane potential of greater than -80 mV and is inhibited by the presence of cholesterol in membranes. Thus bacterial cytoplasmic membranes, being cholesterol-free and having a high transmembrane electrical potential gradient (of -140 niV), are favored for peptide insertion, whereas eukaryotic cell membranes having a low gradient (-15 mV or so) and including cholesterol are not.
The above process occurs in both Gram-positive and Gram-negative bacteria. However, an additional interaction must occur in Gram-negative bacteria, i.e. with the outer membrane. We have provided substantial data [8] to indicate that the mechanism utilized by cationic peptides to cross the outer membrane is selfpronioted uptake. In this mechanism the cationic peptides physically interact with divalent-cation-binding sites on surface lipopolysaccharide and, being bulkier than the divalent cations they displace, cause a perturbation of the outer membrane through which uptake of other cationic peptide molecules is promoted. This mechanism explains two of the other antibacterial activities of cationic peptides, namely enhancer and anti-endotoxin activities. Presumably those peptides that are selective for Gram-negative bacteria (e.g. cecropins) have their activities actually enhanced by this primary interaction.
CLINICAL CONSIDERATIONS
Every antibiotic introduced into clinical use faces three major issues besides efficacy, namely formulation, toxicity and stability. To date only topical usage of these peptides has been attempted. The first clinical trials of MSI-78 against impetigo failed, probably because of poor clinical trial design (75% cure in the mock-treated controls), but the second clinical trial against diabetic foot ulcer has been claimed by the company Magainin Sciences to demonstrate equivalent efficacy to quinolones. Clearly, the successful passage of peptides into phase 111 clinical trials suggests that the three major concerns described above have been solved for topical usage. However, such usage does not seem to play to the strengths of cationic peptide antibiotics and it is more interesting to consider systemic or organ-specific therapy. With regard to formulation, not much is known. The few published animal trials have largely involved delivery of the cationic peptides in saline 19, 11] . An alternative approach is liposornal formulation, which has been shown to improve the bioavailability and activity in vivo of the peptide indolicidin
The issue of toxicity is a serious one, since there are known cationic peptides which are potent toxins (e.g. melittin, the major toxic component of bee venom). There is very little information about the known cationic peptides, although our own experiences to date show no toxic effects on macrophage tissueculture cells, and no obvious toxicity a t the highest doses in our animal models. Stability is a major issue, too, since proteases abound in the body. Decpite these considerations, we feel that cationic peptides offer exciting prospects as clinical agents and real potential as the first breakthrough class of antibiotics in 25 years. [22] .
